PROJECTS

ACTIVE PROJECTS

We participate in projects mainly focusing on information technologies and biomedical research, including drug design and development, patient engagement or post-marketing surveillance. We are currently involved in the following projects:

PREMIER

Prioritisation and Risk Evaluation of Medicines in the EnviRonment

Budget: €9M (IMI funding programme)
Duration: 2020-2026
Participants: 25 partners
Coordinator: Radboud University Nijmegen

H20

Health Outcomes Observatories

Budget: € 20.4M (IMI funding programme)
Duration: 2020-2025
Participants: 23 partners
Coordinator: Medizinische Univesität Wien

EU-PEARL

EU Patient CEntric ClinicAl TRial PLatforms

Budget: €29M (IMI funding programme)
Duration: 2019-2023
Participants: 36 partners
Coordinator: Vall d’Hebron Research Institute (VHIR)

RESCEU

REspiratory Syncytial Respiratory virus Consortium in EUrope

Budget: €25M (IMI funding programme)
Duration: 2017-2021
Participants: 18 partners
Coordinator: University of Edinburgh

CLOSED PROJECTS

PARADIGM

Patients active in research and dialogues for an improved generation of medicines.

Budget: €9.1M (IMI funding programme)
Duration: 2018-2020
Participants: 34 partners
Coordinator: Forum Europeen Des Patients (EPF)

Members of our team have previously been involved in:

Accelerated development of vaccine benefit-risk collaboration in Europe

Arrhythmogenic potential of drugs

European Medical Information Framework

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities

Genotype-to-Phenotype Databases:A Holistic Solution

AIDS vaccine research project

European Prevention of Alzheimer’s Dementia

Promoting and Monitoring Biomedica Informatics in Europe

Intelligence-led Assessment of Pharmaceuticlas in the Environment

Creating medicaly-driven integrative bioinformatics applications focused on oncology, CNS disorders and biotech companies researching on treatment of neuropathic pain

Strategic alliance between pharmaceutical and biotech companies researching on treatment on neoropathic pain

Safety evaluation on Adverse Reactions in Diabetes

Safety of non-Steroidal anti-inflammatory drugs

Enhancing TRANslational SAFEty Assessment through Integrative Knowledge Management

“Every brilliant experiment, like every great work of art, starts with an act of imagination.”

JONAH LEHRER